<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074616</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-19-0518</org_study_id>
    <nct_id>NCT04074616</nct_id>
  </id_info>
  <brief_title>Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation</brief_title>
  <acronym>TTNS-RCT</acronym>
  <official_title>Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve
      stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life
      using TTNS at home
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized sham-control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Study is designed to look at the difference in &quot;high dose&quot; group, which will be submotor amperage, compared to &quot;low dose&quot; which will be set to 1 mA. Both groups will need to stimulate the tibial nerve and visualize toe movement, and then decrease to the amperage of either &quot;high dose&quot; or &quot;low dose.&quot; Both groups will use the device for 30 minutes, 5 days per week. A urodynamic study will be performed to measure bladder capacity, sensations while filling, and detrusor pressures before starting using the device and one last time at the end of the study.
We are also conducting surveys to describe differences in preferences with using bladder medications versus devices.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with reduction in bladder medication</measure>
    <time_frame>3 months after subject enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with reduced neurogenic bladder symptoms (NGB) as measured by the neurogenic bladder symptom score (NBSS)scale.</measure>
    <time_frame>3 months after subject enrollment</time_frame>
    <description>The NBSS scale consists of 24 questions each with a score ranging form 0-4.Higher the score indicates a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with reduced neurogenic bladder symptoms (NGB) as measured by the voiding dairy</measure>
    <time_frame>3 months after subject enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with improved quality of life as assessed by the I-QOL questionnaire</measure>
    <time_frame>3 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with decreased anticholinergic side effects as measured by the anticholinergic side effects survey</measure>
    <time_frame>3 months after subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with stable or improved bladder capacity as assessed by the urodynamic study</measure>
    <time_frame>At baseline and 3 month after subject enrollment</time_frame>
    <description>urodynamic study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Spinal Cord Injury</condition>
  <condition>Neurogenic Bladder</condition>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low dose TTNS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High Dose</intervention_name>
    <description>Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.</description>
    <arm_group_label>High Dose</arm_group_label>
    <other_name>TTNS stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low dose</intervention_name>
    <description>Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>TTNS stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SCI performing IC

          -  Up to 2 anticholinergic overactive bladder (OAB) medications

          -  No changes in OAB medications

          -  Neurologic level of injury above T10

          -  English and Spanish speaking

        Exclusion Criteria:

          -  Past history of genitourinary diagnoses or surgeries

          -  History of central nervous system (CNS) disorders and/or peripheral neuropathy

          -  Pregnancy

          -  Lower motor neuron bladder

          -  Concern for tibial nerve pathway injury

          -  Absence of toe flexion or AD with electric stimulation

          -  Bladder chemodenervation in past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Argyos Stampas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Argyrios Stampas, MD</last_name>
    <phone>713-797-5938</phone>
    <email>argyrios.stampas@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Bernal, BS</last_name>
    <phone>713-797-7636</phone>
    <email>vanessa.bernal@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stampas Argyrios, MD</last_name>
      <phone>713-797-5938</phone>
      <email>argyrios.stampas@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Bernal</last_name>
      <phone>7137977636</phone>
      <phone_ext>l</phone_ext>
      <email>vanessa.bernal@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ackery A, Tator C, Krassioukov A. A global perspective on spinal cord injury epidemiology. J Neurotrauma. 2004 Oct;21(10):1355-70. Review.</citation>
    <PMID>15672627</PMID>
  </reference>
  <reference>
    <citation>Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology. 2000 Apr;55(4):490-4.</citation>
    <PMID>10736489</PMID>
  </reference>
  <reference>
    <citation>Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, Pannek J, Radziszewski P, Wyndaele JJ. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009 Jul;56(1):81-8. doi: 10.1016/j.eururo.2009.04.028. Epub 2009 Apr 21.</citation>
    <PMID>19403235</PMID>
  </reference>
  <reference>
    <citation>Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma. 2004 Oct;21(10):1371-83.</citation>
    <PMID>15672628</PMID>
  </reference>
  <reference>
    <citation>Chaabane W, Guillotreau J, Castel-Lacanal E, Abu-Anz S, De Boissezon X, Malavaud B, Marque P, Sarramon JP, Rischmann P, Game X. Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study. Neurourol Urodyn. 2011 Apr;30(4):547-50. doi: 10.1002/nau.21009.</citation>
    <PMID>21488095</PMID>
  </reference>
  <reference>
    <citation>Chen G, Liao L, Li Y. The possible role of percutaneous tibial nerve stimulation using adhesive skin surface electrodes in patients with neurogenic detrusor overactivity secondary to spinal cord injury. Int Urol Nephrol. 2015 Mar;47(3):451-5. doi: 10.1007/s11255-015-0911-6. Epub 2015 Jan 22.</citation>
    <PMID>25609546</PMID>
  </reference>
  <reference>
    <citation>McDonald JW 3rd, Sadowsky CL, Stampas A. The changing field of rehabilitation: optimizing spontaneous regeneration and functional recovery. Handb Clin Neurol. 2012;109:317-36. doi: 10.1016/B978-0-444-52137-8.00020-6. Review.</citation>
    <PMID>23098722</PMID>
  </reference>
  <reference>
    <citation>Stampas A, Tansey KE. Spinal cord injury medicine and rehabilitation. Semin Neurol. 2014 Nov;34(5):524-33. doi: 10.1055/s-0034-1396006. Epub 2014 Dec 17. Review.</citation>
    <PMID>25520024</PMID>
  </reference>
  <reference>
    <citation>Stampas A, York HS, O'Dell MW. Is the Routine Use of a Functional Electrical Stimulation Cycle for Lower Limb Movement Standard of Care for Acute Spinal Cord Injury Rehabilitation? PM R. 2017 May;9(5):521-528. doi: 10.1016/j.pmrj.2017.03.005.</citation>
    <PMID>28526124</PMID>
  </reference>
  <reference>
    <citation>Stampas A, Korupolu R, Zhu L, Smith CP, Gustafson K. Safety, Feasibility, and Efficacy of Transcutaneous Tibial Nerve Stimulation in Acute Spinal Cord Injury Neurogenic Bladder: A Randomized Control Pilot Trial. Neuromodulation. 2019 Aug;22(6):716-722. doi: 10.1111/ner.12855. Epub 2018 Oct 3.</citation>
    <PMID>30284350</PMID>
  </reference>
  <reference>
    <citation>del Popolo G, Mencarini M, Nelli F, Lazzeri M. Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: a literature overview. Spinal Cord. 2012 Jan;50(1):8-13. doi: 10.1038/sc.2011.110. Epub 2011 Nov 1. Review.</citation>
    <PMID>22042300</PMID>
  </reference>
  <reference>
    <citation>Canbaz Kabay S, Kabay S, Mestan E, Cetiner M, Ayas S, Sevim M, Ozden H, Karaman HO. Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12-months results. Neurourol Urodyn. 2017 Jan;36(1):104-110. doi: 10.1002/nau.22868. Epub 2015 Sep 9.</citation>
    <PMID>26352904</PMID>
  </reference>
  <reference>
    <citation>Sirls ER, Killinger KA, Boura JA, Peters KM. Percutaneous Tibial Nerve Stimulation in the Office Setting: Real-world Experience of Over 100 Patients. Urology. 2018 Mar;113:34-39. doi: 10.1016/j.urology.2017.11.026. Epub 2017 Nov 28.</citation>
    <PMID>29196071</PMID>
  </reference>
  <reference>
    <citation>Fougere RJ, Currie KD, Nigro MK, Stothers L, Rapoport D, Krassioukov AV. Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury. J Neurotrauma. 2016 Sep 15;33(18):1651-7. doi: 10.1089/neu.2015.4278. Epub 2016 Apr 13.</citation>
    <PMID>26980078</PMID>
  </reference>
  <reference>
    <citation>Sievert KD, Amend B, Gakis G, Toomey P, Badke A, Kaps HP, Stenzl A. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010 Jan;67(1):74-84. doi: 10.1002/ana.21814.</citation>
    <PMID>20186953</PMID>
  </reference>
  <reference>
    <citation>de Sèze M, Raibaut P, Gallien P, Even-Schneider A, Denys P, Bonniaud V, Gamé X, Amarenco G. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011 Mar;30(3):306-11. doi: 10.1002/nau.20958. Epub 2011 Feb 8.</citation>
    <PMID>21305588</PMID>
  </reference>
  <reference>
    <citation>Sanford MT, Suskind AM. Neuromodulation in neurogenic bladder. Transl Androl Urol. 2016 Feb;5(1):117-26. doi: 10.3978/j.issn.2223-4683.2015.12.01. Review.</citation>
    <PMID>26904417</PMID>
  </reference>
  <reference>
    <citation>Stampas A, Gustafson K, Korupolu R, Smith C, Zhu L, Li S. Bladder Neuromodulation in Acute Spinal Cord Injury via Transcutaneous Tibial Nerve Stimulation: Cystometrogram and Autonomic Nervous System Evidence From a Randomized Control Pilot Trial. Front Neurosci. 2019 Feb 19;13:119. doi: 10.3389/fnins.2019.00119. eCollection 2019.</citation>
    <PMID>30837835</PMID>
  </reference>
  <reference>
    <citation>Dubeau CE. The aging lower urinary tract. J Urol. 2006 Mar;175(3 Pt 2):S11-5. Review.</citation>
    <PMID>16458733</PMID>
  </reference>
  <reference>
    <citation>Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007 May;88(5):646-52.</citation>
    <PMID>17466735</PMID>
  </reference>
  <reference>
    <citation>Welk B, Lenherr S, Elliott S, Stoffel J, Presson AP, Zhang C, Myers JB. The Neurogenic Bladder Symptom Score (NBSS): a secondary assessment of its validity, reliability among people with a spinal cord injury. Spinal Cord. 2018 Mar;56(3):259-264. doi: 10.1038/s41393-017-0028-0. Epub 2017 Nov 29.</citation>
    <PMID>29184133</PMID>
  </reference>
  <reference>
    <citation>Welk B, Carlson K, Baverstock R. A pilot study of the responsiveness of the Neurogenic Bladder Symptom Score (NBSS). Can Urol Assoc J. 2017 Dec;11(12):376-378. doi: 10.5489/cuaj.4833. Epub 2017 Nov 1.</citation>
    <PMID>29257742</PMID>
  </reference>
  <reference>
    <citation>Ibrahim JG, Molenberghs G. Missing data methods in longitudinal studies: a review. Test (Madr). 2009 May 1;18(1):1-43.</citation>
    <PMID>21218187</PMID>
  </reference>
  <reference>
    <citation>Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18(2):76-82.</citation>
    <PMID>12964174</PMID>
  </reference>
  <reference>
    <citation>Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008 May;10(5):348-54.</citation>
    <PMID>18453793</PMID>
  </reference>
  <reference>
    <citation>Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002 Jan 25;16(2):269-77.</citation>
    <PMID>11807312</PMID>
  </reference>
  <reference>
    <citation>Gruber-Baldini AL, Velozo C, Romero S, Shulman LM. Validation of the PROMIS(®) measures of self-efficacy for managing chronic conditions. Qual Life Res. 2017 Jul;26(7):1915-1924. doi: 10.1007/s11136-017-1527-3. Epub 2017 Feb 26.</citation>
    <PMID>28239781</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Argyrios Stampas, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>electric stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

